Needham & Company LLC Issues Pessimistic Forecast for Globus Medical (NYSE:GMED) Stock Price

Globus Medical (NYSE:GMED) had its price target reduced by investment analysts at Needham & Company LLC from $117.00 to $100.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Needham & Company LLC‘s price target suggests a potential upside of 41.51% from the company’s current price.

GMED has been the subject of several other research reports. UBS Group started coverage on shares of Globus Medical in a report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price target for the company. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. BMO Capital Markets lowered shares of Globus Medical from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $94.00 to $78.00 in a research note on Friday. Truist Financial decreased their price objective on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research report on Friday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $96.92.

Globus Medical Trading Down 13.2%

Shares of GMED stock opened at $70.67 on Friday. The stock has a market cap of $9.49 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 1.14 and a beta of 0.98. The stock has a 50-day moving average of $77.20 and a 200-day moving average of $83.18. Globus Medical has a 1-year low of $70.39 and a 1-year high of $101.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The company had revenue of $763.72 million during the quarter, compared to the consensus estimate of $792.39 million. Globus Medical had a return on equity of 14.51% and a net margin of 17.76%. The firm’s revenue was down .7% compared to the same quarter last year. During the same period last year, the company earned $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Sell-side analysts forecast that Globus Medical will post 4.99 earnings per share for the current year.

Insider Activity

In related news, Director Ann D. Rhoads sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the sale, the director owned 35,384 shares of the company’s stock, valued at $3,007,640. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Stephen T. Zarrilli sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the sale, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 60,000 shares of company stock valued at $4,838,400 in the last ninety days. 18.38% of the stock is owned by company insiders.

Hedge Funds Weigh In On Globus Medical

A number of institutional investors and hedge funds have recently modified their holdings of the business. Paradigm Capital Management Inc. NY acquired a new stake in shares of Globus Medical during the 2nd quarter worth approximately $70,042,000. American Capital Management Inc. acquired a new position in shares of Globus Medical during the 2nd quarter valued at $51,599,000. Hawk Ridge Capital Management LP acquired a new position in shares of Globus Medical during the 1st quarter valued at $43,078,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Globus Medical by 107.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock valued at $78,656,000 after acquiring an additional 471,875 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in Globus Medical by 4.5% during the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after acquiring an additional 328,217 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors.

More Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

About Globus Medical